Literature DB >> 19168728

Suppression of nitrosative and oxidative stress to reduce cardiac allograft vasculopathy.

Tomomi Hasegawa1, Koichiro Iwanaga, Donald E Hultquist, Hui Liao, Scott H Visovatti, David J Pinsky.   

Abstract

Oxidant injury occurs when an organ is severed from its native blood supply and then reperfused and continues during subsequent periods of immune attack. Experiments here test the hypothesis that an antioxidant given only in the peri-reperfusion period protects against not only oxidative but also nitrosative stress, leading to reduced vasculopathy long after cardiac allotransplantation. Experiments were performed using a murine heterotopic cardiac transplantation model. An antioxidant, in the form of intraperitoneal high-dose riboflavin, was given to recipients during the initial 3 days after transplantation. Antioxidant-treated mice showed significantly longer graft survival than control mice. At 4 h after transplantation, antioxidant treatment significantly reduced graft lipid peroxidation and oxidized DNA and preserved antioxidant enzyme activity. At day 6 posttransplantation, the redox-sensitive transcription factor nuclear factor-kappaB and inducible nitric oxide synthase were significantly reduced following antioxidant treatment, with concomitant reduction of nitrotyrosine. Despite the limited duration of antioxidant treatment, both acute and chronic rejection were significantly suppressed. In vitro experiments confirmed suppression of nitrosative and oxidative stress and cardiomyocyte damage in antioxidant-treated cardiac allografts. Collectively, antioxidant administration during the initial 3 days after transplantation significantly reduces nitrosative and oxidative stress in cardiac allografts, modulates immune responses, and protects against vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168728      PMCID: PMC2670685          DOI: 10.1152/ajpheart.00498.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  31 in total

1.  Alive and kicking: endothelium at the geographic nexus of vascular rejection.

Authors:  Sean P Mazer; David J Pinsky
Journal:  Circ Res       Date:  2002-12-13       Impact factor: 17.367

2.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation.

Authors:  M E Billingham; N R Cary; M E Hammond; J Kemnitz; C Marboe; H A McCallister; D C Snovar; G L Winters; A Zerbe
Journal:  J Heart Transplant       Date:  1990 Nov-Dec

3.  Mouse model of transplant arteriosclerosis: role of intercellular adhesion molecule-1.

Authors:  H Dietrich; Y Hu; Y Zou; S Dirnhofer; R Kleindienst; G Wick; Q Xu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

4.  Role of nitric oxide and superoxide in acute cardiac allograft rejection in rats.

Authors:  E Akizuki; T Akaike; S Okamoto; S Fujii; Y Yamaguchi; M Ogawa; H Maeda
Journal:  Proc Soc Exp Biol Med       Date:  2000-11

5.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

Authors:  J S Beckman; T W Beckman; J Chen; P A Marshall; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

6.  High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre.

Authors:  C Boehnke; U Reuter; U Flach; S Schuh-Hofer; K M Einhäupl; G Arnold
Journal:  Eur J Neurol       Date:  2004-07       Impact factor: 6.089

7.  T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase.

Authors:  Kian Peng Koh; Yinong Wang; Tai Yi; Stephen L Shiao; Marc I Lorber; William C Sessa; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

8.  Overexpression of human copper/zinc superoxide dismutase (SOD1) suppresses ischemia-reperfusion injury and subsequent development of graft coronary artery disease in murine cardiac grafts.

Authors:  Masashi Tanaka; Golnaz K Mokhtari; Raya D Terry; Leora B Balsam; Keun-Ho Lee; Theo Kofidis; Philip S Tsao; Robert C Robbins
Journal:  Circulation       Date:  2004-09-14       Impact factor: 29.690

9.  Selective chemokine and receptor gene expressions in allografts that develop transplant vasculopathy.

Authors:  Kei Horiguchi; Satoru Kitagawa-Sakakida; Yoshiki Sawa; Zhan-zhuo Li; Norihide Fukushima; Ryota Shirakura; Hikaru Matsuda
Journal:  J Heart Lung Transplant       Date:  2002-10       Impact factor: 10.247

10.  Recipient iNOS but not eNOS deficiency reduces luminal narrowing in tracheal allografts.

Authors:  Kanji Minamoto; David J Pinsky
Journal:  J Exp Med       Date:  2002-11-18       Impact factor: 14.307

View more
  4 in total

Review 1.  Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection.

Authors:  Dilip S Nath; Haseeb Illias Basha; Thalachallour Mohanakumar
Journal:  Curr Opin Organ Transplant       Date:  2010-02       Impact factor: 2.640

2.  Serum bilirubin affects graft outcomes through UDP-glucuronosyltransferase sequence variation in kidney transplantation.

Authors:  Jung Pyo Lee; Do Hyoung Kim; Seung Hee Yang; Jin Ho Hwang; Jung Nam An; Sang Il Min; Jongwon Ha; Yun Kyu Oh; Yon Su Kim; Chun Soo Lim
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

3.  Riboflavin along with antibiotics balances reactive oxygen species and inflammatory cytokines and controls Staphylococcus aureus infection by boosting murine macrophage function and regulates inflammation.

Authors:  Somrita Dey; Biswadev Bishayi
Journal:  J Inflamm (Lond)       Date:  2016-11-28       Impact factor: 4.981

4.  Investigation of the Role of Oxidative Stress and Factors Associated with Cardiac Allograft Vasculopathy in Patients after Heart Transplantation.

Authors:  Wioletta Szczurek; Mariusz Gąsior; Ewa Romuk; Michał Skrzypek; Michał Zembala; Bożena Szyguła-Jurkiewicz
Journal:  Oxid Med Cell Longev       Date:  2020-09-15       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.